Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burroni

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|July 4, 2023
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational studyMaya Belhadj, Barbara Burroni, Olivier Kosmider, et al.
Medicine|November 8, 2014
Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literatureJonathan London, Aurélie Grados, Christophe Fermé, et al.
Haematologica|February 24, 2018
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patientsRudy Birsen, Lise Willems, Johan Pallud, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 28, 2025
Follicular helper T-cell lymphomas with EBV-positive neoplastic cells: a rare scenario with diagnostic implicationsBarbara Burroni, Claire Lamaison, Elsa Poullot, et al.
Haematologica|July 14, 2022
Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosisSandrine Lemoine, Clelia Mornet, Isabelle Quintin-Roue, et al.
Hematological Oncology|May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupYannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
Blood|April 26, 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphomaClémentine Sarkozy, Mary Callanan, Catherine Thieblemont, et al.
Blood|November 18, 2023
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patientsHervé Ghesquières, Daphné Krzisch, Emmanuelle Nicolas-Virelizier, et al.
Journal of Translational Medicine|November 6, 2019
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohortDiane Damotte, Sarah Warren, Jennifer Arrondeau, et al.
Oncotarget|April 24, 2018
Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patientsRudy Birsen, Estelle Blanc, Lise Willems, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|July 4, 2023
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational studyMaya Belhadj, Barbara Burroni, Olivier Kosmider, et al.
Medicine|November 8, 2014
Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literatureJonathan London, Aurélie Grados, Christophe Fermé, et al.
Haematologica|February 24, 2018
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patientsRudy Birsen, Lise Willems, Johan Pallud, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 28, 2025
Follicular helper T-cell lymphomas with EBV-positive neoplastic cells: a rare scenario with diagnostic implicationsBarbara Burroni, Claire Lamaison, Elsa Poullot, et al.
Haematologica|July 14, 2022
Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosisSandrine Lemoine, Clelia Mornet, Isabelle Quintin-Roue, et al.
Hematological Oncology|May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupYannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
Blood|April 26, 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphomaClémentine Sarkozy, Mary Callanan, Catherine Thieblemont, et al.
Blood|November 18, 2023
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patientsHervé Ghesquières, Daphné Krzisch, Emmanuelle Nicolas-Virelizier, et al.
Journal of Translational Medicine|November 6, 2019
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohortDiane Damotte, Sarah Warren, Jennifer Arrondeau, et al.
Oncotarget|April 24, 2018
Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patientsRudy Birsen, Estelle Blanc, Lise Willems, et al.
Pageof 6